Purpose: To analyze the relationship between the new TransAtlantic Inter-Society Consensus (TASC II) infrapopliteal classification and limb outcomes among patients with critical limb ischemia (CLI). Methods: A single-center retrospective study was performed on 166 consecutive CLI patients (mean age 71 years; 113 men) undergoing endovascular treatment of 244 infrapopliteal lesions from 2006 to 2013. Patient, procedural, angiographic, and limb outcomes were compared for the new TASC A/B vs C/D classification for infrapopliteal lesions. Binary restenosis was determined by a peak systolic velocity ratio >2.0 by duplex ultrasound on follow-up at 1, 3, 6, and 12 months. Results: Seventy-two (43.4%) patients had TASC A/B lesions, while 94 (56.6%) had TASC C/D patterns of infrapopliteal disease. Baseline demographics and tissue loss (93% vs 94%, p=0.59) were similar between the groups. TASC A/B lesions were shorter (53±35 vs 170±83 mm, p<0.001), less severely stenosed (77%±24% vs 93%±14%, p<0.001), had a larger target vessel diameter (2.9±0.5 vs 2.6±0.5 mm, p<0.001), and were less frequently chronic total occlusions (24% vs 64%, p<0.001) compared with the TASC C/D group. Threeyear freedom from both amputation (85% vs 67%, p=0.02) and major adverse limb events (79% vs 61%, p=0.02) were significantly higher in the TASC A/B group. Technical success rates (95% vs 80%, p<0.001) and 1-year primary patency (58% vs 51%, p=0.04) were higher in the A/B group. Overall 3-year survival was similar between the groups (96% A/B vs 88% C/D, p=0.2). Conclusion: TASC C/D infrapopliteal lesions are associated with higher amputation and major adverse limb events rates and lower primary patency compared with TASC A/B infrapopliteal lesions. Further studies are needed to assess the association between TASC C/D infrapopliteal lesions and clinical outcomes in patients with CLI.
Introduction
Critical limb ischemia (CLI), the most severe form of peripheral artery disease (PAD), has become a global health concern as PAD incidence rates continue to rise. 1 A recent investigation using data from US adults with health insurance coverage estimated annual incidence rates of 2.35% and 0.35% and prevalence rates of 10.69% and 1.33% for PAD and CLI, respectively. 2 CLI is characterized by chronic ischemic pain at rest or tissue loss, such as ulceration or gangrene, and often manifests in the distal lower extremities, including the infrapopliteal arteries. 3 Given the severity and poor prognosis of CLI with conservative management, 3 intervention is typically required.
There are multiple predictors of adverse outcomes among patients with CLI. Established factors associated with increased 2-year mortality in CLI patients include age, body mass index (BMI), nonambulatory status, hemodialysis, cerebrovascular disease, left ventricular ejection fraction <40%, and tissue loss. 4 Several studies have attempted to generate risk assessment models to aid in clinical decision making for management of patients with CLI, 5, 6 but none of these models currently incorporates angiographic information. While it has been suggested that distal PAD is associated with unique characteristics and worse survival outcomes compared to proximal disease, even after controlling for typical risk factors, 7 the impact of lesion location and extent on outcomes in CLI remains uncertain.
In 2015, the TransAtlantic Inter-Society Consensus for the Management of Peripheral Artery Disease (TASC II) guidelines were updated to incorporate a schema for classification of infrapopliteal lesions. 8 In accordance with prior TASC systems, 3, 9 the updated version classifies infrapopliteal lesion morphology into 4 categories (TASC A-D) based on location and severity of lesions: TASC A represents the mildest form of lesion morphology and TASC D constitutes the most severe ( Figure 1) . 8 This proposed TASC II system for infrapopliteal disease suggests an anatomical basis for disease complexity in CLI but has not been validated against outcomes.
This study investigated the hypothesis that the TASC II infrapopliteal classification is associated with adverse events among patients with CLI undergoing endovascular interventions. Determination of the predictive value of TASC II classification for procedural and limb-related outcomes in CLI patients may provide further insight into optimal treatment strategies based on anatomical disease characterization and expand on preexisting risk assessment models.
Methods

Study Design and Data Collection
Retrospective data analysis was performed using the PAD University of California, Davis (PAD-UCD) registry, which contains clinical data for symptomatic patients with PAD who had lower extremity percutaneous interventions between June 1, 2006, and May 1, 2013. 10 All study procedures were approved by the institutional review board.
At the time of analysis, the registry consisted of 1400 PAD patients who had 2000 procedures. All patients presenting with CLI (Rutherford category 4-6) were incorporated in the study. Electronic medical record review was conducted by trained chart abstractors, with verification by a board-certified cardiologist (G.D.S.). Data were collected on baseline demographics, lesion and procedural characteristics, and ankle-brachial (ABI) and toe-brachial (TBI) indices measured at baseline and at 30 days and 1 year after the procedure. Details of the procedure included lesion type (stenosis or occlusion) and whether the intervention involved balloon angioplasty, cutting balloon angioplasty, cryoplasty, atherectomy, and/or stenting.
Quantitative angiography (Xcelera; Philips Medical Systems, Andover, MA, USA) was performed on all target lesions to evaluate the preintervention percentage of diameter stenosis, lesion length, and reference vessel diameter. For this analysis, the preoperative angiograms were reviewed 2 board-certified interventional cardiologists (G.D.S., E.J.A.). The target lesion was determined based on the most proximal location of the involved lesion and extending to the level of the malleolus.
Patient Cohort and Lesion Characterization
During the study period, 166 consecutive CLI patients (mean age 71 years; 113 men) underwent endovascular procedures to treat 244 infrapopliteal lesions that were retrospectively classified utilizing the new TASC II infrapopliteal classification system. 8 A preliminary analysis compared each of the 4 TASC II infrapopliteal lesion groups to determine whether any differences in outcomes existed. There were no differences in outcomes between TASC A and B infrapopliteal lesions (Figure 2 ) or between TASC C and TASC D lesions ( Figure 3 ). Thus, the study patients were dichotomized into a TASC A/B group (n=72, 109 lesions) and a TASC C/D group (n=94, 135 lesions). The baseline patient, lesion, and hemodynamic data are presented in Table 1 .
Definitions and Outcomes
A nonocclusive stenosis was defined as <99% stenosis with antegrade flow on angiography. Occlusions were defined as complete arterial occlusion and absence of antegrade flow. A multilevel intervention referred to patients having critically obstructive disease treated in either the aortoiliac and/ or the femoropopliteal segments in addition to the infrapopliteal lesion. Technical success was defined as evidence of successful revascularization with <50% residual stenosis (<30% with stenting) after angioplasty and absence of flowlimiting dissection or hemodynamically significant translesion gradient (>10 mm Hg at rest or 20 mm Hg with nitroglycerin infusion). Flow-limiting dissection and translesion gradient were identified at the discretion of the operator during the procedure.
Procedural success referred to both technical success and the absence of major adverse events (eg, death, stroke, myocardial infarction, acute limb ischemia, thrombosis, and/or need for urgent/emergent vascular surgery) within 72 hours of the index procedure.
Major adverse limb events (MALE) included major (above-ankle) amputation of the index limb or major repeat revascularization (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis). Binary restenosis was determined by a peak systolic velocity ratio >2.0 by duplex ultrasound at 1, 3, 6, and 12 months.
The primary outcome for the study was freedom from major amputation at 3 years. Secondary outcomes included freedom from MALE, freedom from restenosis (primary patency), amputation-free survival, and overall survival. Amputation-free survival is a composite metric incorporating mortality and freedom from amputation to reflect the increased risk of death in patients requiring amputation.
Statistical Analysis
Descriptive statistics were generated using counts (percentages) for categorical variables and means ± standard deviations for continuous variables. Kaplan-Meier analysis was performed to assess primary and secondary outcomes; the estimates are reported with the 95% confidence intervals (CIs). Unadjusted Cox proportional hazards modeling explored the associations between the TASC II infrapopliteal classification and clinical outcomes; the results are presented as the hazard ratios (HRs) and 95% CIs. The threshold of statistical significance was p<0.05. Analyses were performed using Stata software (version 11.2; StataCorp LP, College Station, TX, USA).
Results
Group Comparison
Baseline patient characteristics and comorbidities were similar between the 2 groups ( Table 1 ). The 94-patient TASC C/D group had a greater percentage of men (75% vs 60%, p=0.04), though the majority of patients in both groups were older males. Hypertension and diabetes mellitus were common comorbidities for the overall study population. The distribution of Rutherford categories was similar between the groups (p=0.59), with the overwhelming majority of patients classified as Rutherford class 5. There was no significant difference in preprocedural ABIs (0.62±0.22 vs 0.66±0.32, p=0.62) or TBIs (0.20±0.15 vs 0.23±0.18, p=0.34) between the TASC A/B and TASC C/D groups ( Table 1) . The TASC C/D group had a greater percentage of patients with noncompressible ABIs (32% vs 19%, p=0.07).
As expected, angiographic target lesion morphology was distinctive between the cohorts (Table 1) . Lesions were significantly longer (170±83 vs 53±35 mm, p<0.001), more severely stenosed (93%±14% vs 77%±24%, p<0.001), and more frequently occluded (64% vs 24%, p<0.001) in the TASC C/D group. In comparison, vessels with TASC A/B lesions were significantly larger in diameter (2.9±0.5 vs 2.6±0.5 mm, p<0.001). The type of endovascular procedure performed did not vary between TASC A/B and TASC C/D lesions, with balloon angioplasty used in the majority of patients; only a minority was treated with stents. Both technical (95% vs 80%, p<0.001) and procedural (97% vs 88%, p=0.03) success rates were higher in the TASC A/B group. Neither group had a significant percentage of procedurerelated complications (Table 2) .
Outcomes
The mean follow-up periods were 1.5 years (range 0-3) in the TASC A/B cohort and 1.4 years (range 0-3) in the TASC C/D group (p=0.9). Overall midterm survival rates were poor for both groups, with 3-year estimates of 42.0% (95% CI 25% to 53%) and 40.0% (95% CI 24% to 55%) in TASC A/B and TASC C/D patients, respectively (HR 1.1, 95% CI 0.7 to 1.7, p=0.8; Figure 4A ). Although there was no difference in mortality, patients in the TASC C/D cohort had significantly more adverse outcomes. Estimates of 3-year major amputation (HR 3.0, 95% CI 1.2 to 7.4, p=0.02; Figure 4B ), 3-year MALE (HR 2.4, 95% CI 1.1 to 5.2, p=0.02; Figure 4C ), and 1-year restenosis (HR 1.7, 95% CI 1.0 to 3.0, p=0.04; Figure 4D ) were significantly higher for patients with TASC C/D lesions. Despite the variability seen in 3-year major amputation rates, 3-year amputationfree survival did not differ based on TASC classification (HR 1.2, 95% CI 0.8 to 1.9, p=0.4; Figure 4E ).
Discussion
In this study, significant differences were seen in outcomes between TASC A/B and TASC C/D infrapopliteal lesions despite similarities in disease severity based on the Rutherford classification. Compared to TASC A/B lesions, infrapopliteal TASC C/D lesions were associated with decreased procedure success, higher major amputation and MALE rates, and worse primary patency after the procedure. There was no difference in midterm mortality or amputation-free survival according to the lesion classification. These results suggest that the TASC II infrapopliteal classification system is predictive of patency and limb outcomes in CLI patients undergoing angiography and peripheral vascular interventions.
The worse outcomes noted in TASC C/D infrapopliteal lesions could be attributed to several factors. By definition, these lesions are more complex than TASC A/B infrapopliteal lesions, which likely contributed to the reduction in procedural success noted in the TASC C/D group. In this study, TASC C/D infrapopliteal target lesions were significantly longer, smaller in diameter, and more likely to be chronic total occlusions. Prior studies have shown that endovascular treatment of infrapopliteal occlusions are associated with lower procedure success than stenotic lesions and that occluded infrapopliteal lesions also tend to be longer. 11, 12 Consistent with these prior findings, procedure success was lower in patients with occlusions, and those with unsuccessfully treated lesions were more likely to require major amputation or die during follow-up. 12 These findings are concordant with those from our study and suggest that advanced treatment techniques may be necessary to enhance procedure success and, consequently, limb salvage in CLI patients with more advanced disease. Several case series have also recently demonstrated successful recanalization of occluded tibial lesions through retrograde pedal access, with minimal procedure-related complications. [13] [14] [15] [16] [17] This and other retrograde techniques may be an option to consider in CLI patients with TASC C/D infrapopliteal lesions that cannot be crossed using standard antegrade strategies due to disease complexity.
Another major contributor to the improved limb outcomes seen in the TASC A/B group in this study could be related to a greater proportion of patients receiving concomitant inflow disease intervention. In the absence of inflow disease, isolated infrapopliteal lesions leading to tissue loss or rest pain is expected if the infrapopliteal lesions are substantial and have high plaque burden (eg, longer, calcified, smaller, and more chronic occlusions). The greater local plaque burden increases the chance of disease recurrence and may limit the effectiveness of single level intervention. Additionally, isolated infrapopliteal disease may represent a more different, perhaps aggressive, disease process with small vessel disease and poorer outflow. Several investigations have corroborated this hypothesis by demonstrating improved patency and limb events in patients undergoing multilevel intervention compared to isolated infrapopliteal disease. 18, 19 Consistent with this, we found a higher rate of multilevel intervention in the TASC A/B group, a contributor to the improved limb outcomes in this cohort. Although endovascular management has in many centers taken precedence over surgical bypass for CLI treatment, restenosis rates remain high following intervention. 20 Recent findings suggest that long-term patency may play a larger role in clinical outcomes than previously thought. A study by Iida et al 21 demonstrated that angiographic restenosis following angioplasty of infrapopliteal lesions was associated with increased time to wound healing and a higher prevalence of patients with nonambulatory status at 12 months after treatment. Baumann et al 22 found that target lesion revascularization was often required to prevent major amputation in CLI patients and enhance clinical outcomes. In addition to having more extensive overall atherosclerotic disease, TASC C/D lesions had significantly worse primary patency during follow-up in our study, both of which may have contributed to the higher rates of amputation and MALE.
Almost all of the patients in this study were treated with balloon angioplasty alone. Preliminary investigations of drug-eluting stents, 23, 24 drug-coated balloons, 25 and or adjunctive atherectomy (eg, laser or orbital) for the treatment of infrapopliteal lesions have reported improvements in patency, although these results have not always been consistent and may not be applicable to real-world lesions. For example, the majority of patients in those studies had shorter lesions that may not be representative of a TASC C or D lesion. Additionally, the overall rate of stenting and/or adjunctive atherectomy was relatively low even for the TASC A/B group as lesion length in this cohort remained longer than seen in many of these investigations. Thus, the role of these emerging technologies in management of "real-world" CLI patients remains an active area of investigation.
Despite an overall increase in an endovascular-first approach for all CLI patients, 26 surgical revascularization for infrapopliteal lesions in CLI is still frequently encountered. Some authors note similar results of patency and limb salvage for individuals with infrapopliteal CLI treated with balloon angioplasty vs surgical revascularization, with surgical revascularization patients having better results than balloon angioplasty when TASC D lesions were present. 27 Other retrospective studies have supported the notion that endovascular therapy is as effective for limb salvage compared to surgical revascularization. 11, 28, 29 To date, there remains only 1 randomized controlled trial comparing balloon angioplasty with surgical revascularization for CLI. 30 In this trial, surgical revascularization showed higher rates of postoperative morbidity and mortality, greater hospital length of stay, and greater initial costs compared with endovascular therapy. However, the overall rates of amputation-free survival were similar between the groups out to 5 years of follow-up. 30 Many questions remain unanswered, particularly whether any differences (or lack of) are related to anatomical site (eg, aortoiliac, femoropopliteal, or infrapopliteal) of the lesions. Additionally, in the BASIL trial 30 and most of the pertinent published series to date, the endovascular arms are relegated to balloon angioplasty alone, which does not accurately reflect contemporary endovascular management of CLI patients. This leaves many operators awaiting the completion of the BEST-CLI trial, which aims to compare "best" surgical therapy with "best" endovascular treatment in the management of patients with CLI. 31 Subgroup analysis of patients with infrapopliteal disease stratified by TASC II classification will be of particular interest.
Results from the present study have several important clinical implications regarding treatment of patients with CLI. More aggressive long-term surveillance should be implemented for patients with TASC C/D infrapopliteal lesions to reduce the risk of adverse limb outcomes. Singh et al 11 demonstrated increased limb salvage rates in patients who underwent concurrent treatment of multiple lesions compared to those who had isolated single-vessel infrapopliteal intervention. This strategy may be an option to consider for CLI patients with more advanced disease. Angiosome-guided therapy has also been proposed as a mechanism to improve wound healing time and limb salvage rates in CLI patients by focusing intervention on the precise vasculature supplying an area of ischemic damage. 32 However, the data are conflicting and a consensus has yet to be reached. [33] [34] [35] This study illustrates the need for further research to identify ways to optimize clinical outcomes for patients with CLI.
Despite differences noted based on TASC infrapopliteal lesion classification, midterm outcomes were poor for the population as a whole. Several recent contemporary retrospective series in CLI patients demonstrated better midterm survival rates of up to 60% at 2 to 3 years. 4, 21 In contrast, the present study yielded more disappointing survival rates of 40% at 3 years. Unlike the other contemporary series, our overall retention rate was relatively lower. Greater retention rates may signify better access to medical care, ensuring adherence to guideline-directed medical therapy and aggressive wound care, which collectively lead to a reduction in adverse outcomes. Furthermore, our series has a greater proportion of patients with known risk factors for increased mortality, such as congestive heart failure, coronary artery disease, and tissue loss, all of which are known to contribute to the overall mortality in patients with CLI. Consistent with these observations and in conjunction with the more contemporary series, our study highlights the need for aggressive medical and wound care in addition to the index revascularization in efforts to improve overall survival in CLI patients.
Limitations
First, this was a retrospective observational study from a single center, and thus results may not be representative of the patient population in its entirety. Additionally, a causal relationship cannot be established for outcomes reported due to lack of randomization. Other confounding factors that may have contributed to the outcomes but were not evaluated in this study include ambulatory status, the presence and extent of underlying infection, overall wound size, and other comorbidities that may predispose to amputation or mortality.
The preliminary form of analysis completed was univariate; given the limited sample size, the potential role of confounders on the reported outcome was not assessed using multivariate analyses. This study also focused exclusively on endovascular treatment of CLI. It would also be of interest to assess the relationship between the TASC II infrapopliteal classification and outcomes from CLI patients undergoing surgical bypass to determine if similar trends exist. Finally, because of the modest sample size, it was not possible to perform an adjusted analysis to determine the independent association between TASC II infrapopliteal classification and clinical outcomes.
Conclusion
Findings from this study demonstrated that TASC C/D infrapopliteal lesions in patients with CLI are associated with worse primary patency, as well as higher amputation and MALE rates. The updated TASC II classification system for infrapopliteal lesions is predictive of patency and midterm limb outcomes and may serve as a useful tool. Still, the prognosis for patients with CLI remains poor, and novel therapeutic strategies are needed to improve clinical outcomes in this high-risk subset of patients.
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